Iain Clark is an assistant professor of bioengineering at the University of California, Berkeley, and a faculty affiliate at the California Institute for Quantitative Biosciences. His research combines tools from multiple disciplines—molecular biology, microfluidics, engineering, and bioinformatics, to study infectious diseases, central nervous system inflammation, and neural circuit connectivity. As a postdoctoral fellow at Harvard Medical School, Iain pioneered molecular methods for brain connectomics. His postdoctoral work in the Abate Lab at the University of California, San Francisco, involved development of novel microfluidic tools for single-cell analysis.
Iain received a BS from Cornell University and an MS from the University of California, Davis (both in biological engineering); later he earned a PhD in environmental engineering from U.C. Berkeley.
Tony Godfrey is a professor of surgery and computational biomedicine at Boston University. A co-founder of Gothenburg, Sweden, based SimSen Diagnostics, his research interests include cancer biomarkers and molecular pathology (with a particular focus on technique development and clinical application of novel genomic technologies). Since 2001, he has received continuous funding from the National Institutes of Health for his role as an independent investigator. He is a standing member of the National Cancer Institute’s Cancer Biomarkers Study Section and serves as a peer reviewer for many influential journals. Tony is a member of the scientific advisory boards of the DeGregorio Family Foundation as well as that of Fluent BioSciences (where he guides efforts to evaluate our technologies in oncologic clinical applications), and a past member of the Cepheid scientific advisory board.
He obtained a PhD from London’s Brunel University and completed postdoctoral work at the University of California, San Francisco.
Gary brings to Fluent BioSciences his vast business-development experience in DNA sequencing and other genomics technologies (such as microarrays, PCR, imaging, and more). He gained that experience working at Affymetrix, Life Technologies, and Agilent. Now, as an investor-entrepreneur, Gary helps startups evaluate markets, gauge partnering opportunities, and weigh investor interest in areas that include liquid biopsy assays and tools, sequencing, sample prep, genome editing, and therapeutics.
He received a BS and PhD from Stanford University School of Medicine’s Genetics Department.